Who’s Disrupting — and Funding — the AI Boom

Changing Fed policy in 2024 is likely to bring down yields from these increasingly popular funds. Here’s what investors can consider instead.----- Transcript -----Welcome to Thoughts on the Market. I'm Andrew Sheets, Head of Corporate Credit Research at Morgan Stanley. Along with my colleagues bringing you a variety of perspectives, I'll be talking about trends across the investment landscape and how we put those ideas together. It's Friday, January 12th at 2 p.m. in London. One of the biggest stories in recent years has been the rise of the money market fund. Today, an investor in a US dollar money market fund earns a yield of about 5.3%, a full 1% higher than the yield on a 30 year US government bond and almost 4% higher than the yield on the S&P 500. All investment strategy at the moment, to some extent, flows from the starting point that holding cash pays pretty well. Unsurprisingly, those high yields in money market funds for little volatility have been popular. Per data from the Investment Company Institute, U.S. money market fund assets now stand at about $6 trillion, over $1 trillion higher than a year ago, which flows into these funds accelerating over the last few months. But we think this could change looking into 2024. The catalyst will be greater confidence that the Federal Reserve has not just stopped raising interest rates, but will start to cut them. If short term rates are set to fall, the outlook for holders of a money market fund changes. Suddenly they may want to lock in those high current yields. Morgan Stanley expects the declines and what these money market funds may earn to be significant. We see the Fed reducing rates by 100 basis points in 2024, and another 200 basis points in 2025, leaving short term rates to be a full 3% lower than current levels over the next two years. In Europe, rates on money market funds may fall 2% over the same period. While lower short term interest rates can make holding money market funds less attractive, they make holding bonds more attractive. Looking back over the last 40 years, the end of Federal Reserve rate increases, as well as the start of interest rate cuts has often driven higher returns for high quality bonds. But would a shift out of money market funds into bonds make sense for household allocations? We think so. Looking at data from the Federal Reserve back to the 1950s, we see that household allocation to bonds remain relatively low, while exposures to the stock market remain historically high. And this is the reason why we think any flows out of money market funds are more likely to go into bonds than stocks. Stock market exposure is already high, and stocks represent a much more volatile asset than bonds, relative to holding cash. While the US money market funds saw $1 trillion of inflows into 2024 flows to investment grade and high yield saw almost nothing. That is starting to change. With the Fed done raising rates, we expect higher flows into credit, especially in 1 to 5 year investment grade bonds, the part of the credit market that could be the easiest first step for investors coming out of cash and looking for something to move into. Thanks for listening. Subscribe to Thoughts on the Market on Apple Podcasts, or wherever you listen, and leave us a review. We'd love to hear from you.

12 Jan 20243min

Investors are split on the outlook for natural gas as “peak shale” may be on the horizon. Here’s what to expect in 2024.----- Transcript -----Welcome to Thoughts on the Market. I'm Devin McDermott, Head of Morgan Stanley's North American Energy Research Team and the Lead Commodity Strategist for Global Gas and LNG Markets. Today, I'll be talking about some of the big debates around natural gas and shale in 2024. It's Thursday, January 11th at 10 a.m. in New York. The evolution of shale as a viable, low cost energy resource, has been one of the biggest structural changes in global oil and gas markets of the past few decades. In oil, this turned the U.S. into the world's largest producer, while falling costs also led to sharp deflation in prices and global oversupply. For U.S. natural gas, which is more regionally isolated, it allowed the market to double in size from 2010 to 2020, with demand growing rapidly across nearly every major end-market. Over this period, the U.S. transitioned from a net importer of liquefied natural gas, or LNG, to one of the world's largest exporters. But despite this robust growth, prices actually declined 80% over the period as falling cost of U.S. shale and pipeline expansions unlocked low cost supply. Now looking ahead after a multi-year pause, the US is set to begin another cycle of LNG expansion. This comes in response to some of the market shocks from the Russia/Ukraine conflict, including loss of Russian gas into Europe, as well as strong demand growth in Asia, where LNG serves as a key energy transition fuel. In total, projects that are currently under construction should nearly double US LNG export capacity by the later part of this decade. While the last wave didn't drive prices higher, this time can be different as it comes at a time when some investors feel like peak shale might be on the horizon. Shale is maturing, well costs and break-evens are generally no longer falling, and pipe expansions have slowed significantly due to regulatory challenges. While many of these issues are more apparent on the oil side, there are challenges for gas as well. Notably, the lowest cost US supply region, the Marcellus in Appalachia, is constrained by lack of infrastructure. As a result, meeting this demand likely elicits a call on supply growth from higher cost regions relative to last cycle. This not only includes the Haynesville, a gas play in Louisiana, but also the Eagle Ford in Texas and Basins in Oklahoma, potentially requiring prices in the $4 to $5 per MMBtu range to incentivize sufficient investment. Investors are split on the natural gas outlook. Bears argue that abundant, low cost domestic supply will meet LNG demand without higher prices, just like last time, while bulls backed higher prices this time around. Now, strong supply and a mild start to the winter heating season has actually pushed Henry Hub prices lower to close out 2023, bringing year-to-date declines to 50%. While this drives a softer set up for the first half of 2024, lower prices also come with a silver lining. This should help moderate potential investment in new supply ahead of the pending wave of LNG expansions. As a result, we believe the bearish near-term setup may prove bullish for the second half of 2024 and 2025. A dynamic many stocks in the sector do not fully reflect. Thanks for listening. If you enjoy the show, please leave us a review on Apple Podcasts and share Thoughts on the Market with a friend or colleague today.

11 Jan 20243min

World oil demand is slowing, non-OPEC supply remains strong and OPEC is likely to follow through on planned cuts. Here’s how investors can understand this precarious balance.----- Transcript -----Welcome to Thoughts on the Market. I'm Martjin Rats, Morgan Stanley's Global Commodity Strategist. Along with my colleagues bringing you a variety of perspectives, today I'll discuss the 2024 Global Outlook for oil. It's Wednesday, the 10th of January at 2 p.m. in London. Around six months ago, oil market forecasters widely forecasted a tight second half for 2023 with considerable inventory draws. This expectation was partially driven by two factors. One, OPEC cuts, and in particular the additional voluntary cut of about 1 million barrels a day announced by Saudi Arabia back in June that took the country's production to 9 million barrels a day, about 10% lower than the average of the first half of 2023. The second factor was a positive view on demand, which had mostly surprised to the upside in the first half of 2023. The market indeed tightened in the third quarter and inventories drew sharply at the time. As a result, Dated Brant rallied and briefly reached $98 a barrel in late September. However, this was not to last in the fourth quarter. Demand disappointed, growth and non-OPEC supply remained relentless and inventories built again. Needless to say, these trends have been reflected in prices. Not only did spot prices decline, Dated Brant fell to about $74 a barrel in mid-December, but a number of other indicators, such as calendar spreads for example, signaled a broad weakening of the oil complex. Looking ahead, we expect a relatively precarious balance in 2024. Demand growth is set to slow as the post-Covid recovery tailwinds have largely run out of steam by now. Despite low investment in production capacity in recent years, the growth in non-OPEC supply is set to remain strong in 2024 and probably also in 2025, enough to meet all global demand growth. Naturally, this limits the room in the oil market for OPEC oil. When OPEC cuts production in response, as it has recently been doing, this puts downward pressure on its market share and upward pressure on its spare capacity. History warns of such periods. On several occasions when non-OPEC supply growth outpaced global demand, eventually, a period of lower prices was needed to reverse that balance. However, we argue that is not quite what lies ahead for 2024. OPEC cohesion has been robust in recent years and will likely continue this year. We expect the production cuts agreed to in late November 2023 to eventually be extended through all of 2024, and we don't exclude a further deepening of those cuts either. This would limit the pace of inventory builds in 2024, but probably not prevent them. In our base case projections, we still see inventories built modestly at a rate of about a few hundred thousand barrels a day this year, and our initial 2025 estimates also imply a modest oversupply next year. As a result, we see lower oil prices ahead, but again, not a large difference. We estimate Dated Brant will remain close to $80 a barrel in the first half of 2024, but may gradually decline towards the end of the year, trading in the low to mid $70s in 2025. That may also support our economists' call for inflation to moderate further this year. Thanks for listening. If you enjoy the show, please leave us a review on Apple Podcasts and share Thoughts on the Market with a friend or colleague today.

10 Jan 20243min

Companies that offer generative AI solutions saw their valuations rise in 2023. This year, investors should look at the companies adopting these solutions.----- Transcript -----Welcome to Thoughts on the Market. I’m Ed Stanley, Morgan Stanley's Head of Thematic Research in Europe. And along with my colleagues, bringing you a variety of perspectives, today I'll discuss our views on the broad impacts of AI across global markets. It's Tuesday, the 9th of January at 2 p.m. in London. AI has established itself as a critical theme of the last 12 months, but we are clearly in the early innings of its diffusion. More specifically, 2023 was very successful for AI players that we call the enablers, those first line of hardware and software companies that play into the generative AI debate. But after the first wave of excitement, how does that trend percolate through the rest of the market, and how much of the hype will translate to sustainable earnings uplift? What is the next move for this entire debate, which so captivated markets in 2023? Our team mapped out the next stage of the debate across all regions and industries, and came to three key conclusions. The first, looking back at 2023, the enablers did extraordinarily well, and that shouldn't come as a surprise to any of our regular listeners. Some of those companies saw triple digit returns last year, and we estimate that more than $6 trillion of market cap was added to those names globally. But that brings us to our second key conclusion. Namely, looking forward, we think that investors should now turn their attention to the adopters. Meaning companies that are leveraging the enablers software and hardware to better use their own data and monetize that for the AI world. Looking back last year, where the enablers returned more comfortably double digit and triple digit returns, the adopters only gained on average around 6%. Of course, we're only in the early innings of the AI revolution, and the market is still treating these adopters as a "show me" story. We think that 2024 is going to be transformative for this adopter group, and we expect to see a wave of product launches using large language models and generative AI, particularly in the second half of 2024. Our third key conclusion is around the rate of change. And what do we mean by this? Well, in 2023, the enabler stocks, where AI was moderately important to the investment debate, increased their total market cap by around 28%. But if AI increases in importance to the point where analysts deem it to be core to the thesis for that particular stock, we expect it can add another 40% to market cap of this group based on last year's performance. A final point worth noting is that investors should pay close attention to the give and take between enabler and adopter groups. As I mentioned, the adopters were relatively more muted in their performance last year than the enablers. However, we believe in 2024 we will see the virtuous cycle between these two groups come into greater focus for investors. Enablers, consensus upgrades and valuations will depend increasingly on the enterprise IT budgets being deployed by the adopters in 2024-25. The adopters, in turn, are in a race to build both revenue generating and productivity enhancing tools, which completes the virtuous circle by feeding the enablers revenue line. Thanks for listening. If you enjoy the show, please leave us a review on Apple Podcasts and share Thoughts on the Market with a friend or a colleague today.

9 Jan 20243min

Investors worry that anti-obesity drugs could dent demand for medical procedures and devices. Here’s what they could be missing.----- Transcript -----Welcome to Thoughts on the Market. I'm Patrick Wood, Morgan Stanley's MedTech analyst. And today, I'll be talking about the potential impact of anti-obesity medications on the MedTech industry. It's Monday, January 8th at 10 a.m. in New York. Anti-obesity drugs have made significant gains in popularity over the past year, and by and large, the market expects them to disrupt numerous MedTech markets as widespread adoption leads to population-level weight reduction and co-morbidity improvement. To a certain extent, we agree with the premise that obesity is linked to high health care spend and therefore anti-obesity drugs could represent a risk to device sales. Our research suggests that moderate obesity is associated with about $1,500 a year higher spend on healthcare per capita, with an even greater impact in severe obesity at about $3000 bucks a year. But we think it would be a mistake to assume reduced rates of obesity are intrinsically negative for medtech makers overall. In fact, we think anti-obesity drugs may ultimately prove to be a net positive for MedTech companies as the drugs increased life expectancy and increased demand for procedures or therapies that would not have been a good option for patients who are obese. In some cases, severe obesity can actually be contraindication for ortho or spine surgery, with many patients denied procedures until they shed a certain amount of weight for fear of complications, infection, and other issues. In this context, anti-obesity drugs could actually boost procedure volumes for certain patients. Another factor to consider, we believe the importance of life expectancy shifts as a result of potentially lower obesity rates cannot be ignored. In fact, our analysis suggests that obesity reduces life expectancy by about ten years in younger adults and five years in middle age adults. Think of it this way, from the standpoint of total healthcare consumption, one incremental year of life expectancy in old age could equate to as much as ten years of obesity in terms of overall healthcare spending. Adults 65 plus spend 2 to 3 times more per year on average, than adults 45 to 64, with a significant $10 to $25,000 step up in dollar terms. Furthermore, rates of sudden cardiac death increased dramatically in high body mass index patients, eliminating the possibility of medical intervention to address the underlying obesity issue or the associated co-morbidities. Given all this, we think anti-obesity drugs will ultimately prove to be a net benefit for cardiovascular device makers overall, even in certain categories where body mass index is correlated with higher procedure rates. In markets such as structural heart, where we're replacing things like heart valves, we believe the number of patients reaching old age, that is 70 plus, is most important in regards to volumes. Though rates of obesity are contributing factors as well, orthopedics is more of a mixed bag. The strongest evidence we've seen here is on lower BMI's leading to reduced procedure volumes though pertaining to osteoarthritis in the knees and degenerative disc disease in spine. But we think the argument that fewer people with obesity means fewer knee replacements or fewer incidences of spine disease is actually only half the picture. Clearly, age may be a factor here, and our sense is that hip volumes in particular are not dependent on high BMI's as much as on an aging population. To sum up, we believe that anti-obesity drugs won't dismantle core MedTech markets. There are more layers to the story here.Thanks for listening. If you enjoyed the show, please leave us a review on Apple Podcasts and share Thoughts on the Market with a friend or colleague today.

8 Jan 20243min

Should investors be concerned about a sluggish beginning to the year, or do they just need to be patient?----- Transcript -----Welcome to Thoughts on the Market. I'm Andrew Sheets, Head of Corporate Credit Research at Morgan Stanley. Along with my colleagues bringing you a variety of perspectives, I'll be talking about trends across the global investment landscape and how we put those ideas together. It's Friday, January 5th at 2 p.m. in London. 2023 saw a strong finish to a strong year, with stocks higher, spreads and yields lower and minimal market volatility. That strength in turn flowed from three converging hopeful factors. First, there was great economic data, which generally pointed to a US economy that was growing with inflation moderating. Second, we had helpful so-called technical factors such as depressed investor sentiment and the historical tendency for markets, especially credit markets, to do well in the last two months of the year. And third, we had reasonable valuations which had cheapened up quite a bit in October. Even more broadly, 2024 offered and still offers a lot to look forward to. Morgan Stanley's economists see global growth holding up as inflation in the U.S. and Europe come down. Major central banks from the US to Europe to Latin America should start cutting rates in 2024, while so-called quantitative tightening or the shrinking of central bank balance sheets should begin to wind down. And more specifically, for credit, we see 2024 as a year of strong demand for corporate bonds, against more modest levels of bond issuance, a positive balance of supply versus demand. So why, given all of these positives, has January gotten off to a rocky, sluggish start? It's perhaps because those good things don't necessarily arrive right away. Starting with the economic data, Morgan Stanley's economists forecast that the recent decline in inflation, so helpful to the rally over November and December, will see a bumpier path over the next several months, leaving the Fed to wait until June to make their first rate cut. The overall trend is still for lower, better inflation in 2024, but the near-term picture may be a little murky. Moving to those so-called technical factors, investor sentiment now is substantially higher than where it was in October, making it harder for events to positively surprise. And for credit, seasonally strong performance in November and December often gives way to somewhat weaker January and February returns. At least if we look at the performance over the last ten years. And finally, valuations where the cheapening in October was so helpful to the recent rally, have entered the year richer, across stocks, bonds and credit. None of these, in our view, are insurmountable problems, and the base case expectation from Morgan Stanley's economists means there is still a lot to look forward to in 2024. From better growth, to lower inflation, to easier monetary policy. The strong end of 2023 may just mean that some extra patience is required to get there. Thanks for listening. Subscribe to Thoughts on the Market on Apple Podcasts or wherever you listen, and leave us a review. We'd love to hear from you.

5 Jan 20243min

Many investors believe that the value of Japanese stocks will dip as the yen gets stronger. Here’s why we’re forecasting ~10% growth.----- Transcript -----Welcome to Thoughts on the Market. I'm Daniel Blake from Morgan Stanley's Asia and Emerging Market Equity Strategy team. Along with my colleagues, bringing you a variety of perspectives, today I'll discuss one of the big debates in the market around Japanese equities in 2024. It's Thursday, January 4th at 10 a.m. in Singapore.. As we kick off the new year, one of the most debated investor questions is whether Japanese equities can again perform well if the Yen is now over weakening, but instead strengthens over 2024 as expectations of Fed rate cuts play out. The market is understandably concerned that if the Yen appreciates significantly, Japanese equities will underperform, given the impact on competitiveness and the effects translation of foreign earnings. As a result, global investors remain underweight on Japanese equities versus their benchmark weight, despite the notably improved sentiment on the underlying Japanese economy. So in contrast to these concerns, we believe that Japanese equities and the Yen can simultaneously rally in 2024, which will mean even stronger returns for unhedged dollar based investors than for the local index. Our currency strategists forecast modest further gains in the Yen, with a pick up to 140 against the US dollar by end 2024 versus 143 today. And despite this, we see corporate earnings growth still achieving 9% in 2024, underpinned by nominal GDP recovery and corporate reforms. So what is the reason for the break in the usually negative relationship between the yen and Japanese equities? We still see three drivers supporting the market. First, there’s the return of nominal GDP growth. The Japanese economy is finally exiting deflation that has been prevalent since the 1990s, and we believe a virtuous cycle of higher nominal growth in Japan has started thanks to joint efforts from the Bank of Japan and the corporate sector to move to a positive feedback loop between price hikes and wage growth, underpinned by a productive CapEx cycle. Our chief Japan economist, Takeshi Yamaguchi, forecasts nominal GDP growth for 2023 to have achieved 5%, but to remain above 3% growth in 2024, and a healthy 2 to 2.5 % for the foreseeable future. The second driver is corporate reforms, which have been the most crucial driver of underlying Japanese equities performance, and we expect the trend improvement of return on equity to continue. The sea change in corporate governance in Japan has led to major changes in buyback and dividend policies, which combined are almost quadruple the levels they were at ten years ago. And we're seeing a broadening trend of underlying business restructuring underpinned by more engagement from investors, both foreign and domestic. Finally, Japan has been a net beneficiary of investment inflows and CapEx orders in the transition to a more multipolar world. And with those flows, while equity valuations are cheap to history, in contrast to the US market, we expect them to be supported by further foreign inflows and domestic inflows that will be boosted by the launch of the new Nippon Individual Savings Account Program this month. Bottom line Japan equities remain our top pick globally. We see the TOPIX index moving further into a secular bull market with our December 2024 target for the index standing at 2,600, which implies 10% upside in Yen terms and more in US dollar terms from current levels. Thanks for listening. And if you enjoy the show, please leave us a review on Apple Podcasts and share Thoughts on the Market with a friend or colleague today.

4 Jan 20243min

Tune in as our analysts take a look back at the major themes from 2023 and a look ahead to what investors should be eyeing in 2024.----- Transcript -----Paul Walsh: Welcome to Thoughts on the Market. I'm Paul Walsh, Morgan Stanley's European Head of Research Product. And on this special episode of the podcast, we'll take a look back at 2023, which has been an extraordinary year. And we'll also touch on what 2024 could have in store for investors. It's Wednesday, January the 3rd at 2 p.m. in London. Paul Walsh: At the start of last year, we identified ten overarching long term themes that we believed would command investor focus throughout 2023 and beyond. And they ranged from macro developments like inflation, China's reopening and India's economic transformation to micro oriented themes such as Chat GPT, obesity, drugs and a number of others. Of course, the year did throw in a few curveballs, so I wanted to sit down with Ed Stanley to review some of the major themes that did hold investor interest last year, and that will likely continue to unfold in 2024. Paul Walsh: The whole energy and utilities space has been a topic of constant debate, be it at the energy transition or what's been going on around energy security. And then slightly more sort of sector specific with some of the micro dynamics, we've had the value of innovation in pharma at work around GLP-1s proving to be tremendously popular, as one would expect. And clearly the proliferation of artificial intelligence has really been, you know, the other non macro big theme this year, which has been tremendously prevalent, pretty much whichever corner you've looked in. If I take a little bit of a step back, Ed, and I think about the global themes that we've tried to own this year, namely multipolar world, decarbonization and tech diffusion, from a thematics perspective what themes worked and what played out in the way that you thought, and where have we seen things happening that were unexpected? Ed Stanley: I think the three big themes that you talk about remain as relevant, if not more relevant now than when we started the year. If you think about tech diffusion, A.I. has been the theme of the year. In multipolar world, we've had more conflict this year, and obviously that kind of sharpens people's minds to what stocks will and won't work in this kind of backdrop. And then if you think about the decarb theme as the final structural theme, higher interest rates are making investors really question whether the net zero transition is on track. So those three themes remain super relevant. We talked about the China reopening that sort of worked and then it was a bit of a disappointment mid and later on in the year. I'd say we got the micro probably better nailed down than the macro, but in a volatile year, I think we did a fairly good job of picking what to watch out for. Paul Walsh: What themes have people not been talking about that have been on your radar screen over recent years that you think could make a resurgence as we look forwards? Ed Stanley: There is a kind of joke in the tech world that we go in three year cycles, so we have A.I, then we have Web3, which is de facto crypto, and then we go back to AR/VR and we run in these cycles waiting for whatever breakthrough comes next. We've had crypto having another rally and we've had A.I this year, so we've had sort of all of them this year, but those are always rotating on the back burner. There are always things like unexpected news in quantum computing that could have overflow and disruption effects across the economy, which most investors are not thinking about until it becomes relevant. So I think there are a lot of things in the background which very easily could thrust themselves into the core of the debate.Paul Walsh: Well, let's talk a little bit about that and think about what we should be looking out for 2024. So how are you thinking about how the sort of themes and the landscape across the themes is going to develop into 2024 Ed, and what listeners should be thinking about? Ed Stanley: I think if you think on the top down three structural themes, there is very little to change our view that those remain pretty quarter to our thinking. If you think maybe geographically and then from a micro perspective, geographically, not much has changed on our view on the US, we're threading a needle on that. I think what is more of a shift is a much greater focus on Japan and India relative to China and the US. I think the debate will shift a bit, we won't leave generative A.I behind by any means, but we will shift probably more to talking about EDGE A.I. That is where A.I. is being done on your consumer device, in effect rather than in a data center. And this is something where we see many more catalysts. We see the prospect of killer apps emerging in 2024 to really thrust that debate into people's consciousness. So I think you'll be hearing more about EDGE. So now is the time to get clued up on that if it's not on your radar screen. I think if we're keeping up with the healthcare space, obesity will obviously carry on as a debate, but I think, you know, another piece is on smart chemo. And this is a great topic where there are more catalysts coming up. Not an awful lot is being priced into the underlying equities. Where I think there are exciting things to look forward to. And then the final one is what happens to decarbon renewables. This is a huge debate, but this is the question where you have highly polarized views on both sides. Paul Walsh: Ed, thanks for sharing your views and for all of your great insights through 2023. And we really look forward to what I'm sure will be an interesting and exciting 2024. Ed Stanley: Thank you. Paul Walsh: And to our listeners, thanks for listening. If you enjoy Thoughts on the Market, please leave us a review on Apple Podcasts and do share the podcast with a friend or colleague today.

3 Jan 20245min